Home / Transcripts / Nanosonics Limited (NAN) · February 24, 2026

Nanosonics Limited (NAN) Earnings Call Transcript

February 24, 2026

Australian Securities Exchange AU Health Care Health Care Equipment and Supplies earnings 43 min

Earnings Call Speaker Segments

Catherine Strong executive
#1

Good day, everyone, and welcome to Nanosonics' FY26 half year results. I'm Catherine Strong, Head of Investor Relations and Corporate Communications at Nanosonics. At the start of this webinar, everyone will be in listen-only mode, and we'll hear a presentation of the results from Michael Kavanagh, Chief Executive Officer and President, along with Jason Burris, Chief Financial Officer. While they present, the management team will walk through a selection of the slides that were lodged with the ASX earlier this morning, and those will be shown through the webinar. Should you have joined via conference call only, you might prefer to also join through the webinar. A question and answer session will come after the presentation. To ask a question, simply press the star key and then the number 1 on your telephone keypad. I'd now like to pass the call to Michael Kavanagh.

Michael Kavanagh executive
#2

Thanks so much, Catherine, and good morning to everyone — appreciate you all being here. At this point, I'd imagine quite a few of you have already looked through, and maybe had a chance to skim, the results for our first half, which I think show yet another strong and encouraging six months for the organization on both the financial and operational fronts. The materials submitted contain plenty of detail, and before we dig into some of that, there are a handful of key points I want to flag up front. First, the company keeps delivering growth in a disciplined way. Revenue, as you'll have noticed, rose 9% against PCP, with operating margin up 27%, and that comes from cost growth held to just 4% through discipline. Recurring revenue across consumables and service is still climbing, all of it supported, naturally, by the ongoing expansion of our installed base of trophon devices. As you'll have seen, upgrades are now contributing quite meaningfully to growth as well. In fact, during the half we achieved 20% total unit installation growth, which reflects both solid new installed base placements and a record level of upgrades in North America.

Michael Kavanagh executive
#3

This performance shows customers continuing to favor the trophon solution, and it's worth noting that during the first half, most of the upgrades were in fact to trophon2 — bearing in mind that our next-generation platform, the trophon3, launched midway through that period, and that a lot of the units in our pipeline were quite far along in the budget approval process, so they stayed with the trophon2. While that mix, along with large volume deals, tempers average selling prices near term, these trophon2 installations can definitely keep meaningfully growing our recurring revenue opportunity base and certainly put us in a good position for software-led value capture over time, because those trophon2s now have access to trophon2 Plus, which effectively gives them the chance to upgrade via software to the trophon3 platform — which is why many of them chose the trophon2 given where they stood in the budget approval process. The CORIS commercialization is moving forward as planned, with key milestones met during the half, and you'll have seen Friday's announcement about the start of the controlled market release in the UK, which of course represents a really important milestone and, of course, with more to come in the not-too-distant future.

Michael Kavanagh executive
#4

To wrap up, we reiterate our full-year guidance. We anticipate sustained expansion in core consumables and services, together with continued growth in capital unit volume — we reiterate our guidance for the full year. Before diving into some specifics, a quick reminder, particularly for anyone new to the story: each year at Nanosonics, our technologies help safeguard millions of people around the world against cross-contamination risk, thanks to our leadership in ultrasound probe reprocessing via the trophon platform. With 38 — just over 38,000 trophon devices installed globally — we keep witnessing the power of a large and expanding installed base that drives recurring revenue, and capital revenue too, as we keep driving upgrades and keep delivering value to customers. Meanwhile, with CORIS, our innovative endoscope cleaning device, now entering the commercialization phase, we believe we hold a compelling opportunity to bring our proven reprocessing and automation expertise into endoscope reprocessing and, we hope, unlock a significant new growth avenue for the business. Turning to a quick look at several financial highlights: the first half produced very solid operating performance, with revenue of $102 million, which rose 9% against PCP, or 8% in constant currency.

Michael Kavanagh executive
#5

That result shows momentum continuing in both our recurring revenue and our capital revenue streams. Just as we had forecast and laid out at the August full year results, gross profit margin percentage did ease somewhat, coming in at 76.3% for the half, and tariffs drove that, though we also saw some higher air freight as well as the mix of products between capital and consumables, since capital—especially the upgrades—is starting to take effect. Importantly, those gross margin effects had been expected and were handled inside our wider financial framework. In that process, we kept a disciplined approach to cost management, and operating expenses rose only 4%, to $69.5 million. It also matters that we keep investing to back our ongoing growth strategy in R&D and in the key growth priorities for the business. This operating leverage translated into a 27% expansion in operating margin for the business, with operating profit reaching $8.5 million. EBIT on a consolidated basis came to $8.4 million, which represents a 3% decline on a reported basis. On a constant currency basis, though, EBIT actually rose 15%, and that demonstrates the strong underlying performance of the business. The constant currency view, of course, accounts for the impact of foreign currency movements in the first half, when there was a net loss of $0.7 million versus a gain of $1.3 million in the prior corresponding period—a $2 million swing in the realized net foreign FX movements.

Michael Kavanagh executive
#6

In a similar vein, profit before tax came in at $8.4 million, representing a 13% increase at constant currency, in fact. Overall, I'd say these results really underscore the strengths and resilience of our business model as a whole, since revenue growth combined with disciplined cost management translated into meaningful earnings for the half. Beyond the financial performance, the first half also delivered strong operating progress in innovation, our operations, and digitalization, with every one of these initiatives strengthening the foundations for sustained growth into the future. The slide you'll see presents just a sample of the achievements during the half, and from an innovation standpoint, as you're all aware, we moved the trophon platform forward by launching the next-generation trophon3 and the trophon2 software upgrade midway through the period, which is helping capital sales growth volume and will keep helping it going forward. We also hit important milestones with CORIS, obtaining our regulatory registrations across Australia, Europe, and the UK, and taking important steps toward the phased commercial rollout of the product. Furthermore, we filed our first 510(k) application for expanded scope indications, and once again, that further reinforces the long-term growth pathway for CORIS, and that 510(k) is currently under review by the FDA.

Michael Kavanagh executive
#7

On the operational side, we also had a few notable wins during the first half. We locked in and signed a new headquarters location, with relocation targeted for approximately April 2027. That new headquarters — which additionally features a larger manufacturing and technical facility — is going to considerably reinforce our worldwide operating backbone and put us in position to scale efficiently as the company keeps expanding. Also significant in the half: we brought in fresh leadership talent to steer key areas of the business through the coming growth phase, including Bill Hayden as the new Regional President for North America, plus Kimberley Hill as the new Chief Marketing Officer and Head of Asia-Pacific. And lastly, we advanced meaningfully on the digital front, rolling out the new ERP system successfully and going live with our cloud-based traceability solutions. Those cloud-based efforts genuinely boost visibility, efficiency, and customer engagement, and they establish a solid digital foundation for future growth. All in all, the progress achieved in the first half, I believe, shows a business executing well, investing with discipline, and steadily building capabilities to deliver scalable, profitable growth over the long term.

Michael Kavanagh executive
#8

Now I'll pass things over to Jason, who will walk us through some of those financial details a bit more closely. Jason.

Jason Burriss executive
#9

Thanks, Michael, and good morning, everyone. This slide shows how our core business model keeps performing strongly. We closed the half with 38,080 devices in the global installed base, which is up 6% versus the prior corresponding period and reflects ongoing momentum in new installed base devices. That growing footprint matters fundamentally to the way we grow the business and, crucially, to the way we protect patients. As of today, that installed base helps protect roughly 29 million patients annually. This scale feeds straight through into recurring revenue growth. Recurring revenue rose 9% on PCP, powered by solid results in both consumables and service. Core consumables grew in line with the installed base, ecosystem consumables keep expanding, and service and repairs posted strong growth of 24%, which reflects deeper customer engagement and the maturity of the fleet. Spare parts, as you can see, fell 23% on PCP, mainly because of customer inventory dynamics and lower replacement needs as more customers upgrade to newer generation systems. Turning to installations, this underscores how strong our installation activity was in the half and the quality of demand we are seeing across our customer base. Total installations rose 20% on the prior period to 2,070 devices, reflecting continued momentum in new placements and, importantly, a record level of upgrade activity in North America.

Jason Burriss executive
#10

That upgrade cycle really is a central engine behind the value we build over the long run. It brings the installed base up to date, deepens the ties we have with customers, and underpins recurring revenue via consumables, service, and the connectivity products we've recently introduced. As Michael noted, most of those upgrades during the half went to trophon2 units — bearing in mind that trophon3 arrived midway through the period, and customers had already made substantial headway getting budget sign-off for trophon2 upgrades. Capital revenue rose 9% versus the prior period, hitting $26.5 million for the half. That figure covered a number of sizable upgrade agreements, and the capital revenue increase mirrors volume-based pricing, which produced a somewhat softer average selling price for trophon. Crucially, we expect these trophon2 upgrades to support software-driven value capture down the road through the trophon2 Plus software offerings. Moving to the P&L, we're still showing robust operating leverage, since operating margin is climbing more quickly than revenue — a sign of the continued discipline we apply to running and scaling the business. As Michael said earlier, total revenue was up 9%, landing at $102.2 million for the half, with gains in both recurring and capital revenue. Gross profit margin came in at 76.3%. That's a 2.2-point decline year on year, as anticipated, driven by the effects of US tariffs along with some air freight headwinds and product mix impacts.

Jason Burriss executive
#11

Meanwhile, we kept a firm grip on operating expense discipline—OpEx rose only 4%, far slower than revenue—even as we kept funding priority areas such as R&D. With the big development programs maturing, R&D has come down as a share of revenue, which shows rising efficiency while our dedication to innovation stays intact. EBIT came to $8.4 million, a decrease of 3%. That reported EBIT drop mirrors FX movements, since this half brought a net FX loss against a gain a year earlier. Excluding currency effects, EBIT was up 15%. Let me spend a moment to elaborate on that final point. In H1 26, EBIT took a hit from an FX loss of $0.7 million. That stems from revaluing non-Australian dollar asset balances—chiefly US dollar asset balances—as of 31 December '25. The loss came about as the Aussie dollar strengthened against the US dollar to $0.67, roughly 2%, and most of it is unrealized FX losses. Profit before tax reached $10.6 million, 3% lower, yet again higher in constant currency terms at +13%. Better operating leverage: this slide illustrates how we are pushing operating margin expansion via gross margin and cost control. Gross profit margin climbed 6% to $78 million.

Jason Burriss executive
#12

Meanwhile, we kept a firm grip on operating expense discipline, holding OpEx growth to 4% — considerably lower than revenue growth — even as we kept putting money into our priority growth initiatives. That combination produced meaningful operating margin expansion, with operating margin rising 27% to $8.5 million in the half, which shows our ability to scale the business, manage cost pressures, and keep expanding margins through disciplined execution. We continue to break out the trophon-only business, highlighting its strength and scalability. The trophon-only business delivered operating margin of $25.6 million, representing 20% growth on the prior period. This business also delivered 9% EBIT growth. Importantly, operating margin as a percentage of sales expanded to 25%, up from 22.9%. This demonstrates the operating leverage inherent in the trophon business model, with high-margin recurring revenue continuing to scale efficiently as the installed base grows. The trophon business also continued to generate significant cash, providing funding capacity for working capital, ongoing investment in CORIS, and our broader long-term growth strategy, while maintaining strong financial flexibility. With that, just turning briefly to cash and the balance sheet. During the half, cash flow was a modest outflow of about $1.4 million, which reflects our planned investment in inventory as we ramp up for CORIS, continued investment in the CORIS system, and the commencement of our share buyback.

Jason Burriss executive
#13

That also captured when receivables came in, and we've already seen improvement there in January. We've carried out roughly $4 million of the buyback, and we expect to pick it back up in the coming days once the blackout period ends. Key point: we still carry no debt and hold a solid cash position of $159.8 million, which gives us room to put money into growth efforts, back CORIS commercialization, and keep managing capital with discipline. I'll turn it over now to Michael, who will speak briefly about what's driving growth in the trophon business, give an update on CORIS, and walk you through the financial guidance for '26 that we've reaffirmed.

Michael Kavanagh executive
#14

Thanks, Jason. We've discussed the seven growth drivers for our trophon business before. On the capital side, there's the new installed base along with upgrade sales. We just recently rolled out a new capital software upgrade opportunity for every existing and new trophon2 user with the trophon 2 Plus, and through that upgrade, that software delivers many of the new benefits of trophon3 to those users. Then when it comes to consumables, we have the core disinfecting consumables plus a broader set of ecosystem consumables needed for the full reprocessing process, like wipes and clean probe covers, etc. Then, of course, there's the service component — both service contracts or PAYG for those without a service contract. Service, as all of you know, kicks in a year after purchase, since the device carries a one-year warranty period. Then, of course, with the trophon3 and trophon 2 Plus, we have new and broader traceability solutions through the connectivity. There's a robust full ecosystem of growth drivers for the trophon business. On the next slide, this slide sort of pulls them together by showing how each of the growth drivers applies over the lifetime of a device. Now, every trophon device typically has a life span of up to 10 years, or sometimes 7 to 10 years, and sometimes longer, after which customers, of course, can then upgrade to the latest generation.

Michael Kavanagh executive
#15

That's what we're observing right now as EPRs get upgraded to T2s or T3s. Starting from the moment a unit is installed, it starts producing high-quality recurring revenue via those core and ecosystem consumables, and those are able to scale alongside customer procedure volume. Should ultrasound procedure volumes rise, well, those consumable products rise as well. After that, over time, service and repair contracts complement it, and that clearly assists customers in protecting their devices as well as uptime and the overall performance of the technology. Naturally, looking forward, I just noted that connectivity plus software-based subscriptions are able to further strengthen this model. For the customer, these offerings genuinely support compliance, traceability, and workflow efficiency, while of course adding one more layer to our recurring revenue. Taken together, this mix of capital, upgrades, and several recurring revenue streams genuinely does underpin the strength, resilience, and scalability of the trophon franchise. As Jason highlighted, the trophon-only business's own performance in the first half is an excellent one. Turning quickly to CORIS, during the half, as I already noted, we successfully reached a number of key milestones. As I said, we submitted the first 510(k) for expanded scope indications, and that is in the US, and we are currently awaiting the FDA's determination on it.

Michael Kavanagh executive
#16

We secured regulatory registrations for the device across Europe, the UK, and ANZ. Naturally, after the period ended, we very recently began a controlled market release. Going forward, the milestones ahead of us involve further regulatory submissions to the FDA aimed at expanding the scope of indications even more broadly. We'll be kicking off additional CMRs shortly here in Australia, plus more in Europe, while the US will begin following the 510(k), that first 510(k), and we'll likely hold off and gather some early insights from the initial CMRs before getting started. Wider commercialization is then expected to proceed region by region, depending on when those CMRs wrap up, though as we've said before, we anticipate commercialization beginning in FY27. All in all, CORIS is tracking to plan, with solid progress made and clearly defined next steps as we advance toward full commercialization. The image on the slide is in fact the first unit at our first CMR site in the UK. I can tell you the customers there are pretty enthusiastic, and as the quote shows, they clearly anticipate substantial benefits from the device over time. We're very excited about getting that first CMR underway.

Michael Kavanagh executive
#17

To wrap up, I'll turn to guidance. As I said at the start, we're reaffirming our '26 guidance at constant currency, which shows our continued confidence in the business's underlying performance. With that, we expect ongoing capital unit growth half-on-half, and we note that the capital average selling price from the first half could be expected to carry into H2, and that will totally depend on the T2-T3 mix and the size of upgrade deals. We're very, very happy to look at — there were a number of deals that are quite large, and, of course, it's quite customary to do volume-based pricing for deals like that. We're also expecting recurring revenue to continue to grow, and so all of that together, we expect overall revenue to be within the 8% to 12% as guided back in August. Gross margins, again, we expect to be in the range of 75% to 77%, and that guidance assumes tariff rates to remain at the H1 levels. We also will continue our focus on operating expense discipline into the second half, whilst maintaining the investments that we're making not only in CORIS, but also with other priority growth projects that we're investing in.

Michael Kavanagh executive
#18

Broadly speaking, the outlook we've given balances ongoing expansion, tight control of costs, and long-term investment. Naturally, it's important to point out that this guidance relies on the FX rates we set out on 20 August, when the USD stood at 65 cents. As everyone is aware, we run a currency hedging program that continues as before, and we're all also aware that the Australian dollar has appreciated; were the revenue range restated at an average exchange rate of roughly 70 cents across the second half, factoring hedging in as well, the revenue range would come out approximately 3% lower. To sum up, I believe the company turned in a very solid operational and financial performance during the first half, and we're strongly placed, not just for growth in the second half, but for the future too. On that note, I'll hand things back to the operator for questions.

Operator operator
#19

Thank you. Just a reminder, if you'd like to ask a question, press star, one on your telephone keypad and wait for your name to be announced. Should you want to cancel that request, press star, two. If you're on a speakerphone, please pick up the handset before asking your question. Our first question comes from Shane Storey at Canaccord Genuity. Please go ahead.

Shane Storey analyst
#20

Morning, everyone. I'll begin with Jason, please. Thanks for the approach—I suppose—to viewing the revenue guidance under what you might call changed FX conditions. Could you perhaps help us understand that, and also thanks for the detail on how FX fed into EBIT, but if rates were to remain roughly at current levels, can you give us a sense of how those asset balances not in Australian dollars and, I guess, other sorts of effects might flow through the EBIT line? Thanks.

Jason Burriss executive
#21

Appreciate that, Shane. Regarding the constant currency translations and FX, that page is in the appendix, and our aim there has been to split apart the two separate FX effects. On that page, points 1 and 2 show the FX impacts on the P&L each month, which clearly affect our revenue and partly offset that in our operating expenses. The second piece of constant currency is the revaluation, as at balance date, of asset balances not denominated in Australian dollars. In the discussion I just gave you, that currency moved 2% from the prior balance date, and it cost us roughly $700,000. Computing that at a rate of about 70 cents gives you a movement of some 4, 4.5%. You can run the math and figure out that the effect on an unrealized FX balance in the second half will most likely be 2, 2.5 times what we saw in the first half.

Shane Storey analyst
#22

That's quite useful, thank you. My final question is essentially one I'll direct to Michael, concerning recurring revenue within the USA. Would you be able to share a bit more detail on how the remaining ecosystem components performed, for instance leaving out the sonics consumable on its own?

Michael Kavanagh executive
#23

On the service side of the business, growth was quite strong, coming in at up 24% on PCP. As you saw, obviously, core consumables rose roughly 9% on PCP. The ecosystem was up around 6% on PCP. Recurring revenue has always included spare parts in the past as well, and as Jason explained, spare parts declined in the half. That was somewhat anticipated, because as we now have upgrades to newer machines, well, then spare parts requirements drop temporarily, and so spare parts fell about 23%.

Shane Storey analyst
#24

Thanks. That covers everything I wanted to ask at this point. I'll rejoin the queue. Thanks a lot. Appreciate it.

Operator operator
#25

The next question is from Davin Thillainathan at Goldman Sachs. Please go ahead. Oh,

Davin Thillainathan analyst
#26

Good morning, Michael and Jason. I appreciate you taking my questions. I suppose I'd just like to get a clearer picture of your revenue guidance range of 8% to 12% at constant currency. In the first half, I believe revenues were up roughly 8% on a constant currency basis, so for us to consider that growth rate possibly climbing toward the midpoint of that guidance range, could you help us understand which drivers you're expecting in the second half, please?

Michael Kavanagh executive
#27

To repeat what I said, we are confirming once more that we will land inside that guidance. I believe you witnessed upgrades arriving fairly powerfully; should we keep seeing solid momentum on upgrades, that could definitely assist in getting you to the mid-ranges. There is typically an H2 pop-up in service revenue too, and that simply relates to the timing of service contracts that occur and when the revenue gets realized. Truly, reaching the mid-ranges or upper ranges of the guidance really just requires performance across really the bulk of the growth levers I laid out in the presentation.

Davin Thillainathan analyst
#28

Yeah, thanks. My next question concerns the new US installed base. I believe you did 1,080 units for the half, and that has grown, which is, I suppose, good to see. Could you kind of help us understand your ability to maintain that unit level into the second half? Are there any other dynamics we should be thinking about from a half-on-half perspective, please?

Michael Kavanagh executive
#29

Davin, I think in recent years we've generally given the guidance that here in the US we'd like to believe we can add somewhere between 1,800 and 2,000 new installed base each year, and with the US we feel confident about that. We have visibility into how the pipeline looks, and what you should expect to see is that the count of upgrades, in capital units alone, will overtake or start to overtake the count of new installed base. The important thing is that we're achieving growth on both fronts.

Davin Thillainathan analyst
#30

Yeah, that's right. Thanks a lot. Appreciate it, Michael. That's all from me.

Michael Kavanagh executive
#31

I appreciate that.

Operator operator
#32

Josh Kannourakis from Barrenjoey has the next question. Go ahead, please.

Josh Kannourakis analyst
#33

Hello, Michael and Jason. Can you both hear me clearly? Yes. Great. So, to start with my first question: clearly there was a fair amount of activity involving both upgrades and the installed base during this period, and you highlighted some of the larger-volume deals you closed. When we look ahead to the second half, with some of that visibility in hand, how do you expect that mix to shape up — I mean the split between those bigger-volume deals and possibly somewhat of a shift back toward the more routine as-is business? Or are upgrades likely to simply run higher, given that I suppose we're earlier along the trajectory and thinking about some of the original customers?

Michael Kavanagh executive
#34

When it comes to upgrades, roughly 9,000 EPRs remain in the field. A lot of hospitals have made the EPR their standard of care, so there's still a strong chance for some high-volume deals, and at times those take somewhat longer since they span the whole enterprise, but a real opportunity remains for some high-volume deals, and in fact several sit in our pipeline. All of them come with add-ons for 2, 3, 4, or 5 units as well. We anticipate more high-volume deals arriving in the second half, which is why, in looking at our capital revenue, even though we don't separate those out when giving guidance, we're noting that the ASPs we achieved in the first half may be comparable in the second half given that mix.

Josh Kannourakis analyst
#35

Understood. You also raised a solid point about the extra add-ons, I think, and the chance to upsell those customers over time into the wider ecosystem. From a sales-process standpoint, how do you view the lifecycle of those clients once you bring them on board? And how fast do you believe you could potentially layer in some of those additional features and functionality?

Michael Kavanagh executive
#36

That's a terrific question, and I believe there's a really crucial point worth stressing here: when someone has only just moved up to a trophon2, and even if a lower price comes with that owing to volumes or trade-ins and similar arrangements, the truth is we can still deliver value — additional value — to that customer by means of the software upgrade. Now, it's not likely they'll act on it right away, and frankly, we'd rather have our sales team out in the field pushing all those capital upgrades through as quickly as they can and then circle back. Our new regional president in that territory is definitely examining these matters from an infrastructure standpoint — what kind of structure he should put in place to ensure we're advancing across all seven growth drivers. Your point is very well taken that even with a lower ASP, there's a strong opportunity for us to recapture part of that, and more besides, through software upgrades as time goes on. I think you're going to begin seeing an uptick in those. Some will come in the second half, though I expect considerably more in FY27.

Josh Kannourakis analyst
#37

Great. Then just one more for Jason — the last one — about OpEx. You had good cost control in the period, and obviously you've provided the guidance there as well. As we think about and look toward the CORIS commercialization, which you mentioned is in '27, maybe you could give us a bit of a framework for how we should think about OpEx there. I know obviously that's been a focus for the market, but obviously you already have a pretty established base in terms of infrastructure there — any additional context you can offer on how we should think about incremental sort of OpEx as we get closer to commercialization would be very helpful. Thanks, guys.

Jason Burriss executive
#38

Thanks, Josh. So, I think things will keep going the way they are right now. In our first-half results, you'll notice trophon OpEx came in at +1%, while the OpEx increase was actually driven by CORIS, which rose 16% half-on-half. What we've told you before still holds true today: as CORIS scales up, we'll bring in resources bit by bit to support the sales teams already in place. These could be folks assisting with installations and project management — the kinds of things that will emerge from the controlled market release, which will teach us and help us steer where resource investment is needed so we can roll out CORIS as smoothly and as quickly as we can. They'll be additive, and we keep working to drive the operating leverage we've managed to deliver in earlier halves, and we intend to carry that forward, particularly in the trophon business, through the remainder of '27.

Josh Kannourakis analyst
#39

Understood. I just want to verify that point, though, Jase: as we look at it, there isn't really a significant jump as we move into '27 — it's more of a steady, gradual climb from the half-on-half pattern we'll observe going forward, correct?

Jason Burriss executive
#40

That's right. Yeah, Josh, thanks.

Josh Kannourakis analyst
#41

All right, that's excellent. Appreciate it, everyone.

Operator operator
#42

The following question is from Taj Wesson at RBC Capital Markets. Taj, your line is open.

Taj Wesson analyst
#43

Good morning, everyone. Thanks for taking my question. I’m simply wondering what gives you confidence that your customers fully grasp the value proposition of trophon3 compared with trophon2. As a follow-up, perhaps you could offer additional color on how upgrades break down in the second half across trophon2, trophon2 Plus, and trophon3. Thank you.

Michael Kavanagh executive
#44

If I’m reading the question correctly, it’s really about what gives us confidence that customers will grasp the trophon3 value proposition. Honestly, that comes down to marketing and sales, and making sure that when we’re in front of customers, their job is to help everyone understand. Also, keep in mind that a lot of what’s in trophon3 was driven by customer insights as well. As for the mix between T2 and T3 in the second half, we expect that to start shifting toward T3 over time. Much of what’s driving the current T2 mix is simply where approvals stand and the budget approval processes at hospitals. Ultimately, over time, we expect the absolute majority to move toward trophon3. One other point I’ll make on that is not to underestimate that there are over 25,000-plus trophon2s in the market today as well. It’s not just about talking to customers who are the original EPR customers about trophon3; it’s also about talking over time to all existing trophon2 users, because they now have the opportunity to upgrade with that software, the T2 Plus software, to enable them to access a lot of the benefits of trophon3 as well. That’s a significant opportunity when you think there are 20 over 25,000 of those T2s in operation.

Taj Wesson analyst
#45

Thanks, I appreciate it. What I’m really trying to get at is whether there’s any friction when it comes to how trophon3 is priced compared with trophon2, and whether customers might not grasp that premium that could potentially be unlocked.

Michael Kavanagh executive
#46

No, that isn’t something we’re observing right now.

Taj Wesson analyst
#47

Thanks. And then, regarding the bigger volume deals and the kinds of ASP effects they bring, I was wondering whether that carries over to consumables too — are any concessions being offered as part of those agreements?

Michael Kavanagh executive
#48

Nope. Absolutely not.

Taj Wesson analyst
#49

All right. That's excellent. Thanks a lot. That's very clear.

Michael Kavanagh executive
#50

Great. Thanks. All right, I believe that was the final question. Once more, I'd like to express my appreciation to everyone—I realize it's a hectic morning in the markets today—but in closing, I think the company has turned in a very strong operational and financial showing for the half, and we sit in a robust position, reaffirming guidance for the second half, and not only for the second half but also all the groundwork that has been laid for what lies ahead. I'm looking forward to connecting with many of you in the days ahead. Many thanks.

Read the full transcript via the API

You're viewing the first half of this call. Get the complete Nanosonics Limited transcript - plus 132,000+ transcripts from 7,000+ companies, speaker segments and full-text search - through the EarningsAPI REST API or hosted MCP server.

Get an API key View API docs →

For developers and AI pipelines

Programmatic access to Nanosonics Limited earnings transcripts and 132,000+ others is available through the EarningsAPI REST API and the hosted MCP server. Quarterly plans from $162 - full transcripts, speaker segments, full-text search, and the /api/v1/transcripts/recent polling endpoint for ETL pipelines.